Around the Web

Amyloid gains converts in debate over Alzheimer's treatments

, February 27, 2023

Pharma

Dispute has far-reaching consequences, including whether Medicare will pay for new anti-amyloid drugs.

Overdose reversal medication could soon be sold alongside ibuprofen and allergy meds, but cost may still be a barrier

, February 26, 2023

Pharma

An advisory committee for the FDA unanimously voted last week to support a nonprescription version of Narcan's nasal spray. But the list price could still pose a barrier.

Wall Street backs new class of psychedelic drugs

, February 23, 2023

Pharma

Psychedelic-therapy industry gets a reality trip as investors focus on treatments costing less time and money.

Adderall users struggle with ongoing shortage while reason – and resolution – remain uncertain

, February 23, 2023

Pharma

The FDA says that the manufacturing delay has been resolved and that the shortage is now 'demand-driven.'

SCOTUS refuses to reject $302M judgment against J&J over pelvic mesh marketing

, February 22, 2023

Pharma

SCOTUS refused to hear J&J's appeal regarding a $302 million judgment in a lawsuit brought by California, accusing the company of concealing the risks of its pelvic mesh products.

Ozempic runs low for diabetes patients as weight-loss use surges

, February 22, 2023

Pharma

Around the Web

Amyloid gains converts in debate over Alzheimer's treatments

Dispute has far-reaching consequences, including whether Medicare will pay for new anti-amyloid drugs.

Overdose reversal medication could soon be sold alongside ibuprofen and allergy meds, but cost may still be a barrier

An advisory committee for the FDA unanimously voted last week to support a nonprescription version of Narcan's nasal spray. But the list price could still pose a barrier.

Wall Street backs new class of psychedelic drugs

Psychedelic-therapy industry gets a reality trip as investors focus on treatments costing less time and money.

Adderall users struggle with ongoing shortage while reason – and resolution – remain uncertain

The FDA says that the manufacturing delay has been resolved and that the shortage is now 'demand-driven.'

SCOTUS refuses to reject $302M judgment against J&J over pelvic mesh marketing

SCOTUS refused to hear J&J's appeal regarding a $302 million judgment in a lawsuit brought by California, accusing the company of concealing the risks of its pelvic mesh products.

Ozempic runs low for diabetes patients as weight-loss use surges

Some diabetes patients have had to reduce Ozempic dosing or switch to alternatives.

Pages

Search form

Around the Web

Amyloid gains converts in debate over Alzheimer's treatments

Dispute has far-reaching consequences, including whether Medicare will pay for new anti-amyloid drugs.

Overdose reversal medication could soon be sold alongside ibuprofen and allergy meds, but cost may still be a barrier

An advisory committee for the FDA unanimously voted last week to support a nonprescription version of Narcan's nasal spray. But the list price could still pose a barrier.

Wall Street backs new class of psychedelic drugs

Psychedelic-therapy industry gets a reality trip as investors focus on treatments costing less time and money.

Adderall users struggle with ongoing shortage while reason – and resolution – remain uncertain

The FDA says that the manufacturing delay has been resolved and that the shortage is now 'demand-driven.'

SCOTUS refuses to reject $302M judgment against J&J over pelvic mesh marketing

SCOTUS refused to hear J&J's appeal regarding a $302 million judgment in a lawsuit brought by California, accusing the company of concealing the risks of its pelvic mesh products.

Ozempic runs low for diabetes patients as weight-loss use surges

Some diabetes patients have had to reduce Ozempic dosing or switch to alternatives.

Pages